Reginald Hardy Biography and Net Worth

Chairman of Brickell Biotech

Mr. Hardy has over 25 years of experience in serving as the Chief Executive Officer and/or President for publicly-traded and privately-held pharmaceutical companies.

Prior to Brickell, Reginald was the co-founder and President of Concordia Pharmaceuticals, Inc. an oncology drug development company acquired by Kadmon Corporation in 2011. Mr. Hardy was co-founder and President of SANO Corporation, a pharmaceutical company focused on the development of novel transdermal drug delivery systems that was acquired by Elan Corporation. Prior to SANO, Mr. Hardy served as the President of the generics group at IVAX Corporation. Reginald has also held various corporate roles with Hoechst-Roussel Pharmaceuticals, Inc. and Key Pharmaceuticals, Inc. Mr. Hardy earned his B.S. degree in Pharmacy from the University of North Carolina—Chapel Hill and M.B.A. from UNC-Greensboro.

How old is Reginald L. Hardy?: Mr. Hardy is currently 64 years old. There are 6 older executives and no younger executives at Brickell Biotech. The oldest executive at Brickell Biotech is Mr. Albert Nicholas Marchio II, CFO and Principal Accounting & Financial Officer, who is 70 years old. Learn More on Reginald L. Hardy's age.
How do I contact Reginald L. Hardy?: The corporate mailing address for Mr. Hardy and other Brickell Biotech executives is 5777 CENTRAL AVENUE SUITE 102, BOULDER CO, 80301. Brickell Biotech can also be reached via phone at (720) 505-4755 and via email at [email protected]. Learn More on Reginald L. Hardy's contact information.
Has Reginald L. Hardy been buying or selling shares of Brickell Biotech?: Reginald L. Hardy has not been actively trading shares of Brickell Biotech over the course of the past ninety days. Learn More on Reginald L. Hardy's trading history.
Who are Brickell Biotech's active insiders?: Brickell Biotech's insider roster includes Robert Brown (CEO), Deepak Chadha (Insider), Reginald Hardy (Chairman), David McAvoy (General Counsel), and Andrew Sklawer (COO). Learn More on Brickell Biotech's active insiders.

Reginald L. Hardy Insider Trading History at Brickell Biotech

Reginald L. Hardy Buying and Selling Activity at Brickell Biotech

Brickell Biotech Company Overview

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Today's Range

Now: N/A

50 Day Range

MA: $0.86

$0.77

$0.93

2 Week Range

Now: N/A

Volume

31,300 shs

Average Volume

206,730 shs

Market Capitalization

$6.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.02

Mysterious Gold Leverage Just Announced

From Stansberry Research | Ad

Find out what it is and see how you can get in with just a few dollars.